Compare Stocks

→ The Best AI Stock to Own in the World Today is Trading for Just $25 (From Banyan Hill Publishing) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANCN Anchiano Therapeutics	$0.67 +1.5%	$21.77	$0.51 ▼ $10.55	$4.97M	0.93	3.15 million shs	7,157 shs
CAPR Capricor Therapeutics	$4.82 -2.4%	$5.54	$2.68 ▼ $8.22	$155.62M	3.99	306,569 shs	478,470 shs
ICOTF iCo Therapeutics	$0.34 -5.5%	$0.37	$0.80 ▼ $1.82	$3.09M	2.03	4,760 shs	1,200 shs
XTLB XTL Biopharmaceuticals	$2.59 -2.3%	$3.99	$1.73 ▼ $6.69	$14.44M	1.21	200,233 shs	7,560 shs

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANCN Anchiano Therapeutics	0.00%	-0.12%	-14.31%	+31.98%	-57.70%
CAPR Capricor Therapeutics	-2.43%	-18.72%	-24.45%	+18.14%	+18.43%
ICOTF iCo Therapeutics	0.00%	-3.20%	-0.06%	-8.65%	-11.79%
XTLB XTL Biopharmaceuticals	-2.26%	-0.38%	-1.15%	+192.75%	+112.30%

Biden replacement revealed? (Ad)

A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.

See his shocking evidence in this new report

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ANCN Anchiano Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CAPR Capricor Therapeutics	0.759 of 5 stars	3.5	0.0	0.0	0.0	1.0	0.8	0.6
ICOTF iCo Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
XTLB XTL Biopharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANCN Anchiano Therapeutics	N/A	N/A	N/A	N/A
CAPR Capricor Therapeutics	3.00	Buy	$24.00	397.93% Upside
ICOTF iCo Therapeutics	N/A	N/A	N/A	N/A
XTLB XTL Biopharmaceuticals	N/A	N/A	N/A	N/A

Current Analyst Ratings

Latest XTLB, ICOTF, ANCN, and CAPR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
3/1/2024	CAPR Capricor Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$40.00

(Data available from 4/24/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANCN Anchiano Therapeutics	N/A	N/A	N/A	N/A	$2.01 per share	N/A
CAPR Capricor Therapeutics	$25.18M	6.03	N/A	N/A	$0.73 per share	6.60
ICOTF iCo Therapeutics	N/A	N/A	N/A	N/A	($0.07) per share	N/A
XTLB XTL Biopharmaceuticals	N/A	N/A	N/A	N/A	$0.73 per share	N/A

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANCN Anchiano Therapeutics	-$27.12M	-$3.46	4.47	N/A	N/A	N/A	36.08%	27.40%	N/A
CAPR Capricor Therapeutics	-$22.29M	-$0.87	N/A	40.17	N/A	-88.52%	-299.67%	-45.54%	5/9/2024 (Estimated)
ICOTF iCo Therapeutics	-$1.11M	-$0.40	N/A	∞	N/A	N/A	N/A	-288.85%	N/A
XTLB XTL Biopharmaceuticals	-$1.35M	-$0.42	N/A	∞	N/A	N/A	-73.05%	-68.83%	5/21/2024 (Estimated)

Latest XTLB, ICOTF, ANCN, and CAPR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
2/29/2024	Q4 2023	CAPR Capricor Therapeutics	-$0.23	-$0.02	+$0.21	-$0.02	$5.80 million	$12.09 million

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANCN Anchiano Therapeutics	N/A	N/A	N/A	N/A	N/A
CAPR Capricor Therapeutics	N/A	N/A	N/A	N/A	N/A
ICOTF iCo Therapeutics	N/A	N/A	N/A	N/A	N/A
XTLB XTL Biopharmaceuticals	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANCN Anchiano Therapeutics	N/A	3.25	3.25
CAPR Capricor Therapeutics	N/A	1.63	1.63
ICOTF iCo Therapeutics	N/A	0.72	0.72
XTLB XTL Biopharmaceuticals	N/A	14.09	N/A

Ownership

Institutional Ownership

Company	Institutional Ownership
ANCN Anchiano Therapeutics	9.05%
CAPR Capricor Therapeutics	21.68%
ICOTF iCo Therapeutics	N/A
XTLB XTL Biopharmaceuticals	4.40%

Insider Ownership

Company	Insider Ownership
ANCN Anchiano Therapeutics	6.88%
CAPR Capricor Therapeutics	12.00%
ICOTF iCo Therapeutics	N/A
XTLB XTL Biopharmaceuticals	29.00%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
ANCN Anchiano Therapeutics	16	7.42 million	N/A	Not Optionable
CAPR Capricor Therapeutics	N/A	31.50 million	27.72 million	Optionable
ICOTF iCo Therapeutics	N/A	9.05 million	N/A	Not Optionable
XTLB XTL Biopharmaceuticals	N/A	5.45 million	3.87 million	Not Optionable

XTLB, ICOTF, ANCN, and CAPR Headlines

Source	Headline
	U.S. stocks higher at close of trade; Dow Jones Industrial Average up 1.03% msn.com - March 20 at 8:50 PM
	US Stocks Edge Lower Ahead Of Fed's Decision; General Mills Earnings Top Views msn.com - March 20 at 3:48 PM
	Dow Surges 350 Points; Fed Holds Rates Steady markets.businessinsider.com - March 20 at 3:48 PM
	Crude Oil Surges 2%; Signet Jewelers Shares Spike Higher markets.businessinsider.com - March 20 at 3:48 PM
	XTL To Aquire The Social Proxy globenewswire.com - March 20 at 10:15 AM
	XTL Biopharmaceuticals Ltd ADR (XTLB) investing.com - February 17 at 10:28 AM
	Call for Proposals raps.org - February 11 at 2:00 PM
	XTL Biopharmaceuticals Ltd (H2K2.MU) finance.yahoo.com - October 23 at 11:13 PM
	XTL Biopharmaceuticals Ltd.: XTL Biopharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency finanznachrichten.de - October 23 at 12:16 AM
	XTL Biopharmaceuticals Ltd.: XTL Biopharmaceuticals Confirms that it has not Experienced any Disruption to its Business Operations in Israel finanznachrichten.de - October 21 at 8:22 AM
	XTL Biopharmaceuticals Confirms that it has not Experienced any Disruption to its Business Operations in Israel finance.yahoo.com - October 20 at 7:35 PM
	XTL Biopharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency finance.yahoo.com - October 20 at 7:35 PM
	Is X T L Biopharmaceuticals Ltd (ADR) (XTLB) Stock a Good Investment? aaii.com - March 30 at 3:19 PM
	XTLB XTL Biopharmaceuticals Ltd. seekingalpha.com - October 1 at 8:47 PM
	X T L Biopharmaceuticals Ltd reuters.com - August 8 at 10:32 PM
	LIFE, TBLT and XTLB among pre market gainers seekingalpha.com - July 23 at 7:53 AM
	XTL Biopharmaceuticals Year to Date Total Returns (Daily) ycharts.com - December 18 at 11:24 PM
	XTL Biopharmaceuticals Dividend Per Share (TTM) ycharts.com - December 18 at 1:03 AM
	XTL Biopharmaceuticals Ltd. (XTLB) uk.finance.yahoo.com - December 15 at 10:18 AM
	X.T.L. Biopharmaceuticals Ltd. - ADR money.usnews.com - September 26 at 12:03 AM
	XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB) Up 1.8% This Year: What Should You Expect Next? stocksregister.com - August 23 at 4:44 PM
	Is XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) Expensive At $4.67? Here’s How To Know. marketingsentinel.com - August 20 at 5:09 PM
	How Is XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB) Expected To Fare In The Coming Months? marketingsentinel.com - July 26 at 9:30 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Anchiano Therapeutics

NASDAQ:ANCN

Anchiano Therapeutics Ltd., a preclinical biotechnology company, discovers, develops, and commercializes small molecule anti-cancer therapies. It primarily develops Pan-RAS Program that identifies novel indene-based small molecules that exhibit potent and selective inhibition of activated RAS signaling regardless of isoform or mutation; and PDE10/Ã-catenin program, which identifies small molecules that selectively and potently inhibit PDE10 and suppress Wnt/APC/Ã-catenin signaling in preclinical models. Anchiano Therapeutics Ltd. has collaboration and license agreement with ADT Pharmaceuticals, LLC to research and develop programs related to the pan-RAS and PDE10/Ã-catenin programs. The company was formerly known as BioCancell Ltd. and changed its name Anchiano Therapeutics Ltd. in July 2018. Anchiano Therapeutics Ltd. was founded in 2004 and is headquartered in Cambridge, Massachusetts.

Capricor Therapeutics

NASDAQ:CAPR

Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders.

iCo Therapeutics

OTCMKTS:ICOTF

Satellos Bioscience, Inc. is a regenerative medicine company, which engages in developing novel therapeutics. It operates through a proprietary technology platform, MyoReGenX™ and Leveraging MyoReGenX™, which identify stem cell based regeneration deficits in muscle diseases and develop therapeutic solutions. The company was founded by Frank Gleeson and Michael Rudnicki in 2018 and is headquartered in Toronto, Canada.

XTL Biopharmaceuticals

NASDAQ:XTLB

XTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. Its pipeline includes hCDR1 and Erythropoietin. The company was founded on March 9, 1993 and is headquartered in Ramat Gan, Israel.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial